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Abstract: Background: The objective of the demonstration project for type 2 diabetes prevention in the
Barranquilla and Juan Mina (DEMOJUAN) study was to investigate the extent to which it is possible
to reach normal glucose metabolism with early lifestyle interventions in people at high risk of type 2
diabetes (prediabetes), compared with those who receive standard usual care. Methods: DEMOJUAN
was a randomized controlled trial conducted in Juan Mina and Barranquilla, Northern Colombia.
Eligible participants were randomized into one of three groups (control group, initial nutritional
intervention, and initial physical activity intervention). The duration of the intervention was 24
months. The main study outcome in the present analysis was reversion to normoglycemia. Relative
risks and their corresponding 95% confidence intervals were calculated for reversal to normoglycemia
and T2D incidence. Results: There was no statistically significant association between the intervention
groups and reversion to normoglycemia. The relative risk of reversion to normoglycemia was 0.88
(95% CI 0.70–1.12) for the initial nutritional intervention group participants and 0.95 (95% CI 0.75–1.20)
for the initial physical activity intervention group participants. Conclusions: Our study did not find
any statistically significant differences in reversion to normoglycemia or the development of type 2
diabetes between the intervention groups and the control group in this population.
Keywords: glucose metabolism disorders; primary prevention; South America; population; field trial
1. Introduction
The International Diabetes Federation (IDF) has estimated that the number of adults with diabetes
is expected to rise from 425 million in 2017 to 629 million by 2045 [1]. According to recent data in
2017, the national prevalence of type 2 diabetes (T2D) in Colombia was 8.1% for the 20- to 79-year-old
population, imposing a heavy financial burden on the primary healthcare system [1]. Premature
mortality caused by T2D may lead to 12–14 years of life lost [2].
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Randomized controlled trials carried out in different populations have successfully revealed
that, in people with impaired glucose tolerance (IGT), the progression to T2D can be prevented or
delayed by lifestyle intervention [3–9]. These studies have revealed that nutritional and physical
activity interventions can decrease the relative risk of T2D by 30–60% in people with IGT in controlled
settings [3–9]. The length of the interventions of previously mentioned trials varied between 2.5 and
6 years [3–9]. However, none of these studies included Latin American populations.
Several studies have investigated whether the results of these randomized clinical trials can be
implemented within the primary healthcare system [10–18]. However, the main outcome assessed by
these translational research projects was weight loss, not conversion to normoglycemia, which should
have been the main target. Weight loss was greater, in almost all studies, in the intervention groups
than with the controls. In addition, the majority of the studies did not find differences in blood glucose
or waist circumference. Scientific evidence regarding T2D prevention is lacking from Latin America.
While previous findings offer a compelling evidence base, it is necessary to learn how the
prevention of T2D works in real life in different settings and population groups. In addition, it is
important to find out how well the lifestyle interventions work within the primary healthcare system
in Latin America. Thus far, such trials have not been carried out in the Caribbean region of Latin
America and it is not known whether these lifestyle interventions will work well in a hot and humid
climate, particularly in the physical activity component. The extreme weather conditions seen in the
Caribbean region (thunder storms and humid conditions) may need special logistics and motivation to
improve daily physical activity of the study population.
The main objective of this analysis of the data from the demonstration project for T2D diabetes
prevention in the Barranquilla and Juan Mina (DEMOJUAN) study was to investigate the extent to
which it is possible to reach normal glucose metabolism with early lifestyle interventions in people at
high risk of T2D, compared with those who receive standard therapy (usual care).
2. Materials and Methods
2.1. Study Design and Oversight
The design of the DEMOJUAN study was a three-arm, parallel-group, randomized, and controlled
field trial, using individual random allocation, and was carried out in Juan Mina and Barranquilla,
Northern Colombia [19]. The study site had approximately 1 million inhabitants at the time of
participant recruitment. A trial coordinating center in Barranquilla served as a data and statistical
analysis center and supervised all study sites where patients were recruited and included in the trial.
This project was supported by a BRIDGES Grant from the Global Diabetes Foundation. BRIDGES,
an International Diabetes Federation project, is supported by an educational grant from Lilly Diabetes.
This study followed the Good Clinical Practice guidelines and the guidelines of the Helsinki Declaration.
All data were collected using previously tested questionnaires and methods as much as possible. Aside
from blood samples, no invasive methods were used. The study protocol was approved by the research
ethics committee of the University Pontificia Javeriana, Bogota, Colombia. All the participants gave
their written informed consent prior to participation in the study. The steering committee designed the
study, gathered the data (in collaboration with investigators at the local clinics and other study units),
made the decision to submit the manuscript for publication, and guaranteed the compliance of the
study with the protocol.
The trial was registered at https://clinicaltrials.gov/ (NCT01296100 (2/12/2011)). This work has
been developed following the guidelines of the CONSORT statement, the evidence-based minimum
set of recommendations for reporting randomized trials [20].
2.2. Study Population
The study participants were recruited in the study sites (Juan Mina and Barranquilla) by population
screening, using the Finnish Diabetes Risk Score (FINDRISC) [21–23]. The FINDRISC is based on easily
Int. J. Environ. Res. Public Health 2019, 16, 1403 3 of 13
available information using eight parameters with categorized answers. The total risk score value
ranges from 0 to 26. A FINDRISC of >13 points was considered to be a high risk of having IGT/IFG
or diabetes. The FINDRISC was originally shown to predict the 10-year risk of drug-treated T2D
with a sensitivity of 78–81% and a specificity of 76–77% [21]. Furthermore, it also detects reasonably
prevalent asymptomatic T2D and other disorders of glucose metabolism [23]. The FINDRISC has been
validated in many populations with good results [24–27] and has been successfully applied in primary
care in Barcelona, Spain [19]. It is recommended by the International Diabetes Federation and in the
guideline by the European Society for the Study of Diabetes and the European Society of Cardiology as
a screening tool for T2D [28,29]. In our study, all people with more than 13 FINDRISC points were
invited to an oral glucose tolerance test (OGTT).
Participants 34–69 years of age with a 2-h post-challenge glucose level of 140–200 mg/dL (IGT) or
a fasting plasma glucose level between 100 and 126 mg/dL (impaired fasting glucose) were included
in the study. In addition to the initially defined inclusion criteria when registering the trial, we also
accepted participants with isolated impaired fasting glucose (n = 109) into the study. The reasons for
these changes were numerous. Firstly, people with IFG have a similar risk of progressing to diabetes as
people with IGT. Secondly, there is a lack of knowledge regarding the prevention potential in people
with IFG, since almost all diabetes prevention trials have used IGT as the entry criterion. People with
pharmacologically treated diabetes and hypertriglyceridemia while undergoing drug treatment, a
history of life-limiting diseases or events, and an unwillingness to sign the informed consent were
excluded from the study.
2.3. Randomization and Interventions
Eligible participants were randomly allocated to one of three groups (A, B, or C) with 1:1:1
allocation. The sequences for the random allocation groups were generated by IBM SPSS statistics
version 19.0 for Windows (IBM Corp.: Armonk, NY, USA). The randomization list was prepared by an
independent statistician. Participants and study personnel were aware of the study-group assignments,
but outcome adjudicators were not.
During the following 24 months, the control group (A) received standard treatment (usual care:
Lifestyle advice prescribed by his/her physician). In addition, the participants in the control group
were told about their high risk of T2D and received a “mini-intervention” to improve their lifestyle.
The two intervention groups (Groups B and C) received early intensive lifestyle interventions. Group
B received first a nutritional intervention for 6 months, followed by the physical activity intervention
(6 months), and a combined nutritional and physical activity intervention (12 months). They were also
provided with individual advice about how to achieve the intervention goals. These goals were (i)
reduction in weight of >5%, (ii) total fat intake less than 30% of energy consumed, (iii) saturated fat
intake less than 10 % of energy consumed, and (iv) fruit or vegetable intake of at least 500 g per day.
The participants of group C started with the physical activity intervention (6 months) followed by the
nutritional intervention (6 months). The physical activity intervention consisted of individual visits
with a physical activity specialist and monthly group seminars. Each participant had six individual
visits with a physical activity specialist (four times during the first year and twice in the second year),
where each participant received an individual physical activity prescription. The goal of the physical
activity intervention was to practice moderate-intensity exercise for 30 min a day or more. In addition,
the participants of Groups B and C were divided into groups of 10 participants for the group seminars,
too. The group seminars were held monthly during the first 12 months of the intervention and then
every second month during the second year of the intervention. The group seminars were given
by a nutritionist and physical activity specialist. During the lifestyle intervention period, the study
participants had two study visits at month 1 and 24, respectively. The OGTT was done at month 1 and
month 24. In order to reduce the possibility of bias due to visiting schedule, both intervention groups
had their group sessions and individual visits in parallel, at the same time. However, the seminars
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were held independently for the participants of Groups B and C. The description of the topics of the
lifestyle intervention program are presented in Supplementary file S2.
2.4. Study Measurements
2.4.1. Non-Invasive Measurements
Lifestyle habits and risk factors for T2D were assessed by an interview, using a questionnaire
consisting of information regarding sociodemographic factors, history of T2D, medical history, tobacco
consumption, hypertension, and nutritional and physical activity habits. The instruments applied
were designed based on FINDRISC, the World Health Organization Stepwise approach to surveillance
(STEPS) of non-communicable disease risk factors, and International Physical Activity Questionnaire
(IPAQ) [30,31]. All questionnaires have been successfully validated in large international studies [32–36].
Physical activity measured with the questionnaire shows a high correlation with physical fitness,
measured by maximal oxygen uptake [34–36]. Dietary habits were assessed by 16 questions (e.g.,
dietary pattern, quality and quantity of dietary fat, consumption of fruit and vegetables, grains, milk
and meat products, desserts, sweets, and alcoholic beverages). In addition, 6 questions were related to
perceived needs and intentions to make dietary changes. Scientific validation of the diet questionnaire
was carried out in the National Institute for Health and Welfare in Helsinki, Finland [37]. The study
questionnaire can be found in Supplementary file S1.
All measurements followed a standardized protocol and the staff taking the measurements were
professionals with long-standing experience in measuring anthropometry and blood pressure. Height
and weight were measured without shoes and with light clothing. BMI was calculated as weight (kg)
divided by height2 (m2). Waist circumference (to the nearest cm) was measured at the approximate
midpoint between the lower margin of the last palpable rib and the top of the iliac crest. The categories,
<94 cm vs. ≥94 cm in men and <90 cm vs. ≥90 cm in women, were used to identify abdominal obesity
in the Latin American population [38]. Blood pressure (2 mm Hg precision) was recorded twice with a
mercury sphygmomanometer in a seated position.
2.4.2. Biochemical Measurements
All participants underwent an OGTT that was carried out according to the World Health
Organization (WHO) recommendations [39]. The test started after at least 12 h of fasting, and the
fasting and 2-h blood samples were obtained after oral ingestion of water solution with 75 g anhydrous
glucose. The glucose tolerance status was classified according to the criteria of the American Diabetes
Association [40]. Individuals who had a fasting plasma glucose level ≥126 mg/dL or 2 h plasma
glucose (2hPG) level ≥200 mg/dL were classified as having T2D. Those with 2hPG ≥ 140 mg/dL
but <200 mg/dL, and FPG < 100 mg/dL were classified as having isolated IGT. Isolated IFG was defined
as FPG ≥ 100 but <126 mg/dL, and 2hPG < 140 mg/dL. People with 2hPG ≥ 140 mg/dL but <200 mg/dL,
and FPG ≥ 100 but <126 mg/dL were defined as having combined IGT and IFG. People with T2D, IGT,
or IFG were classified as having IGT.
2.5. Study Outcomes
The main study hypothesis was that the lifestyle interventions would lead to a higher reversion to
normoglycemia, defined as FPG < 100 mg/dL and 2hPG < 140 mg/dL, compared with the control group.
We also evaluated the development of T2D in the study participants.
2.6. Statistical Analysis
The study was designed to have a 90% power to detect a 20% percentage unit difference in recovery
from IGT (comparing 70% vs. 50% recovery rates) between the treatment groups at 5% significance
level. This estimate was chosen due to previous scientific evidence revealing that, as compared with
the placebo, pharmaceutical intervention might increase the conversion rate to normoglycemia from
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50 to 70% in people with IGT [7,41–43]. Assuming a 30% loss to follow up at the end of the 24-month
intervention, a total of 200 participants were needed in both treatment groups (total sample size of 600
individuals). The estimated drop-out of 30% was decided according to the results and experiences
of previous randomized controlled diabetes trials in Europe and the Unites States [6,11,44]. The
data was analyzed using SPSS statistics version 19.0 for Windows with use of the intention-to-treat
approach for all randomly assigned participants. The variables were checked for normality using
Kolmogorov–Smirnoff tests. The χ2 test was used to test differences in the distribution between
categorized variables. Collinearity diagnostics were used to check for correlations between the
variables. Relative risks and their corresponding 95% confidence intervals for the intervention groups
compared with the control groups were calculated for reversal to normoglycemia and T2D incidence.
Differences in FPG and 2hPG among the three groups were assessed using mixed-design analysis of
variance models in order to adjust the estimates for the difference in glucose status at baseline. The
results are expressed as percentages, means, and standard errors/standard deviations. The threshold
for statistical significance was set to 0.05.
3. Results
Figure 1 shows the eligibility, random allocation, and follow-up of the study participants. In total,
14,193 people from the community were screened using the FINDRISC. Those with a FINDRISC of at
least 13 points were invited to an OGTT (n = 4915) and approximately 50% of those invited attended.
Among those with an OGTT result, 1535 did not fulfill the entry criteria of the study, as they had either
normoglycemia or screen-detected T2D. A total of 772 participants were randomly allocated to the
three groups: (A) Control group (n = 246); (B) initial nutritional intervention group (n = 261); and (C)
initial physical activity intervention group (n = 265), respectively. Half of the study participants were
lost during the follow-up of at least 18 months, the final number of study participants that entered the
data analysis process was 122 for the control group (50%), 136 in the nutritional intervention group
(52%), and 132 in the physical activity intervention group (50%).
Figure 1. Eligibility, random allocation, and follow-up of the study participants. Discontinued
intervention refers to participants who discontinued, due to being lost in the follow-up.
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Table 1 presents the baseline characteristics of the study participants after randomization; these
characteristics were mostly equally balanced among the three groups, indicating that the randomization
process worked well in controlling possible confounders.
Table 1. Baseline characteristics of the study participants after randomization.
Intervention Groups
Control Nutrition Physical Activity p-Values
(n = 246) (n = 261) (n = 265)
mean (SD 1) mean (SD) mean (SD)
Age 53.8 (9.1) 52.9 (9.3) 52.2 (8.1) 0.105
% (n) % (n) % (n)
BMI 1 0.218
<25 kg/m2 15 (37) 17 (43) 11 (30)
25–30 kg/m2 36 (88) 41 (106) 44 (115)
>30 kg/m2 49 (121) 43 (111) 45 (119)
Waist circumference 0.59
≥94 cm (men)/≥90 cm (women) 89 (219) 88 (229) 86 (228)
>30 min physical activity/day 13 (31) 13 (35) 15 (40) 0.703
Daily consumption of fruits and vegetables 23 (57) 20 (51) 23 (61) 0.528
Anti-hypertension drug use 46 (114) 44 (115) 46 (121) 0.868
Family history of diabetes 0.657
No 29 (71) 23 (61) 25 (67)
Yes: Grandparent, uncle, aunt, or cousin 22 (54) 26 (67) 23 (61)
Yes: Biological father, mother, or sibling 49 (121) 51 (132) 52 (136)
Previous increased glucose in blood 28 (69) 30 (77) 35 (93) 0.187
Glucose metabolism
Normoglycemia 18 (22) 11 (15) 13 (17) 0.069
Isolated IFG 32 (40) 28 (57) 23 (38)
Isolated IGT 35 (44) 41 (38) 29 (30)
IFG and IGT 15 (19) 20 (28) 35 (47)
1 Standard deviation.
When assessing the baseline characteristics of the three groups for the study participants included
in the analysis (Table 2), it was found that all characteristics were equally distributed, with the exception
of glucose metabolism (p-value < 0.001) at baseline. More study participants in the physical activity
intervention group (36%) had combined IFG and IGT compared with the nutritional intervention
group (21%) or the control group (16%). Normoglycemia and isolated IFG tended to be more frequent
in the control group compared with the two intervention groups.
Table 3 reveals the unadjusted and adjusted results of the logistic regression analysis for the
primary and secondary outcomes of the study. There was no statistically significant difference among
the intervention groups in reversion to normoglycemia. The relative risk of reversion to normoglycemia
was 0.88 (95% CI 0.70–1.12) for the initial nutritional intervention group participants and 0.95 (95% CI
0.75–1.20) for the initial physical activity intervention group participants. Similarly, no statistically
significant association was found among the intervention groups in the incidence of type 2 diabetes.
The corresponding relative risk for the nutritional intervention group was 1.38 (95% CI 0.67–2.84) and
1.43 (95% CI 0.70–2.93), respectively.
The participation rates in the intervention sessions varied according to the type of session (Table 4).
In general, three out of four intervention group participants took part in at least one group and one
individual intervention session. Whereas 32% of the nutritional intervention group participants came
to at least 50% of all planned individual sessions, only 9% had at least a 50% participation rate for the
group sessions. The corresponding participation rates for the physical activity study participants were
46% (individual sessions) and 15% (group sessions).
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Table 2. Baseline characteristics of the study participants included in the analysis.
Effectively Analyzed Control Nutrition Physical Activity p-Values
(n = 122) (n = 136) (n = 132)
mean (SD 1) mean (SD) mean (SD)
Age (years) 53.7 (8.9) 52.3 (9.1) 52.6 (8.2) 0.420
% (n) % (n) % (n)
BMI 1 0.732
<25 kg/m2 13 (16) 18 (24) 13 (17)
25–30 kg/m2 43 (52) 40 (55) 46 (61)
>30 kg/m2 44 (54) 42 (57) 41 (54)
Waist circumference
≥94 cm (men)/≥90 cm (women) 90 (110) 88 (120) 82 (108) 0.118
>30 min physical activity/day 12 (15) 12 (16) 17 (22) 0.444
Daily consumption of fruits and vegetables 28 (34) 19 (26) 24 (32) 0.249
Anti-hypertension drug use 45 (55) 42 (57) 46 (60) 0.815
Family history of diabetes 0.618
No 30 (37) 25 (34) 26 (35)
Yes: Grandparent, uncle, aunt, or cousin 17 (21) 25 (34) 23 (30)
Yes: Biological father, mother, or sibling 53 (64) 50 (68) 51 (67)
Previous increased glucose in blood 27 (33) 27 (36) 36 (48) 0.145
Glucose metabolism <0.001
Normoglycemia 18 (22) 11 (15) 13 (17)
Isolated IFG 35 (43) 27 (36) 23 (30)
Isolated IGT 31 (38) 42 (57) 29 (38)
IFG and IGT 16 (19) 21 (28) 36 (47)
1 Standard deviation.
Table 3. Primary and secondary study outcomes.
Control Nutrition Physical Activity
(n = 122) (n = 136) (n = 132)
RR 1 (95% CI 2) RR (95% CI) RR (95% CI)
Primary outcome
Reversion to normoglycemia 1 Ref. 3 0.88 (0.70–1.12) 0.95 (0.75–1.20)
Secondary outcome
Type 2 diabetes 1 Ref. 1.38 (0.67–2.84) 1.43 (0.70–2.93)
1 Risk ratio; 2 Confidence interval; 3 Reference group.
Table 4. Participation rates of the study participants in the interventions.
Group Control Nutrition Physical Activity
(n = 122) (n = 136) (n = 132)
% (n) % (n) % (n)
Participated in at least one group and one individual
intervention session 0 (0) 74 (100) 76 (100)
Participated in at least 50% of all individual sessions 0 (0) 32 (43) 46 (61)
Participated in at least 50% of all group sessions 0 (0) 9 (12) 15 (20)
Finally, we also calculated the changes in FPG and 2hPG between baseline and after follow-up,
according to intervention group (Table 5). No statistically significant changes were observed in fasting
glucose levels in the three groups (p-value 0.644). However, all study participants showed a decrease
in their 2hPG independently of the group they were assigned to initially (overall p-value < 0.001). The
decrease in 2hPG was 19 mg/dL for the control group, 14 mg/dL for the nutritional intervention group,
and 29 mg/dL for the physical activity intervention group. The p-value for the interaction (intervention
and fasting and 2-h glucose levels between baseline and after follow-up) was 0.201, indicating that
no differences in the changes of the glucose levels were observed between the intervention and
control groups.
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Table 5. Changes in fasting and 2-h glucose levels between baseline and after follow-up, according to
intervention group.
Control Nutrition Physical Activity
(n = 122) (n = 136) (n = 132)
Mean SD 1 Mean SD Mean SD
Fasting glucose
Baseline 97 (10) 101 (10) 102 (11)
After follow-up 101 (19) 102 (21) 106 (32)
p-value for difference between baseline and follow-up = 0.644
2-h glucose
Baseline 143 (25) 141 (26) 146 (26)
After follow-up 122 (43) 127 (52) 117 (49)
p-value for difference between baseline and follow-up <0.001
p-value for differences between intervention groups 0.267
p-value for interaction (intervention and fasting and 2-h glucose levels between baseline and after
follow-up group) 0.201
1 Standard deviation.
4. Discussion
Our study did not find statistically significant differences either in reversion to normoglycemia or
the development of T2D between the intervention groups and the control group. Moreover, 2hPG was
reduced in all three groups, whereas their FPG remained unchanged between baseline and the end of
the study. This is in line with findings from other studies where changes in FPG following lifestyle
intervention has been marginal.
Several studies have tried to implement the findings and experiences of randomized controlled
trials within the primary health-care system [10–15,18]. The DEPLOY study evaluated the delivery
of a group-based Diabetes Prevention Program (DPP) lifestyle intervention in partnership with the
YMCA [10,11]. After six months, body weight decreased by 6.0% (95% CI = 4.7, 7.3) in intervention
participants and 2.0% (95% CI = 0.6, 3.3) [11]. These changes were maintained through 25–32 months
of follow-up [10]. The study initially included 92 study participants and their documented loss in
follow-up during the first 12 months was 37% for the intervention group and 28% for the control
group. A systematic review and meta-analysis of twenty-eight US-based studies applying the findings
of the DPP revealed that the average weight change at twelve months after the intervention was a
loss of about 4% from participants’ baseline weight [12]. Unlike our study, they did not measure
fasting or 2hPG during the follow-up. The Diabetes in Europe: Prevention using Lifestyle, Physical
Activity and Nutritional Intervention (DE-PLAN) project aimed at implementing the strategy of the
Finnish landmark Diabetes Prevention Study (DPS), within several countries in Europe [13,14,18] in
high-risk people identified with the FINDRISC. Similar to our study, those studies had either T2D
or reversion to normoglycemia as a main study outcome [13,14,18]. The first large-scale nationwide
diabetes prevention program in the world, the National Program for the Prevention of T2D (FIN-D2D),
was implemented in Finland during 2003–2008 and evaluated in five hospital districts [18]. They
revealed that the relative risk of T2D was 0.31 (95% CI 0.16–0.59) in the group who lost ≥5% weight, 0.72
(0.46–1.13) in the group who lost 2.5–4.9% weight, and 1.10 (0.77–1.58) in the group who gained ≥2.5%
compared with the group who maintained weight [18]. The DE-PLAN group in Poland included
175 middle-aged, slightly obese participants in nine primary healthcare centers in Krakow [14]. In
keeping with our study results, they did not find changes in FPG or 2hPG in people who participated
in the interventions, but, similar to US-based implementation studies, the Polish intervention led to
a significant reduction in weight during the first 12 months [14]. A prospective cohort study in the
setting of Spanish primary care found that intensive lifestyle interventions were feasible in a primary
Int. J. Environ. Res. Public Health 2019, 16, 1403 9 of 13
care setting and substantially reduced T2D incidence among high-risk individuals [13]. During a
4.2-year median follow-up, they revealed a 36.5% relative risk reduction in the incidence of T2D
between the intervention and control group. The study in the Greater Green Triangle of Southwest
Victoria and Southeast South Australia in 2004–2006 using general practices provided evidence that a
T2D prevention program using lifestyle intervention was feasible in primary health care settings, with
reductions in risk factors approaching those observed in clinical trials, observing T2D in adults with
IGT [15]. Unlike in our study, they reported reductions in FPG and 2hPG in their study participants
during their 12-month intervention.
One important factor explaining the differences of the results between randomized controlled
clinical trials and their implementation in the general population is length of intervention. Whereas
the length of the interventions of the randomized clinical trials varied between 2.5 and 6 years [3–9],
the duration of the interventions of the pragmatic or field trials in the “real world” were of shorter
duration [10–18]. Implementing randomized controlled clinical trials in the population setting has
been shown to have less impact, among others, due to a higher heterogeneity of the study population
and compliance with the interventions. Furthermore, compared with randomized controlled trials,
it is very difficult to reach a very high compliance (or participation rate) with the interventions in
real–life field trials as the study population cannot be controlled in a similar way. However, our study
showed that interventions can be implemented within the primary healthcare system and that at least
reaching reasonable compliance rates for individual sessions may be achieved. Naturally, the reasons
for non-compliance need to be assessed further in order to adapt the program. Thus, this and our short
length of intervention may be some additional reasons why we were not able to show any differences
in changes of the glucose levels between the intervention and the control group.
The problem with translational research in implementing principles of the proof-of-concept
randomized clinical controlled trials in real-life settings is that many factors that can be controlled in
trials cannot be done in routine clinical practice. The political agenda to work on diabetes prevention,
what we believe triggered our project, affects the entire population. Nevertheless, it was of surprise
that an improvement in the glucose profile was observed in both the intervention and control group.
Several reasons may explain these findings. Firstly, probably just participating in this study may
encourage people in the control group to adopt a healthier lifestyle, as also observed in previous
studies (Hawthorne effect). Actually, the participants in our control group were told about their high
risk of T2D, and they also received a “mini-intervention” to improve their lifestyle. Moreover, in
some instances, members of the three groups were from the same community, thus, a dilution of
the intervention from the intervention groups to the control group participants may have occurred.
Secondly, during the study, many activities were carried out by the city of Barranquilla targeting people
with glucose metabolism disorders. For instance, environmental changes were implemented in the
city in the form of creating parks and special sites where people could practice physical activity. In
addition, there were steady information campaigns targeting people with overweight and obesity
to adopt a healthier lifestyle to avoid T2D. Diabetes as a health topic was omnipresent during the
last four years in Barranquilla, until the Ministry of Health of Colombia declared Barranquilla the
national demonstration area for diabetes prevention. Yet another potential explanation of the results
may be partly a regression to the mean of the 2hPG that cannot be fully excluded. However, as study
participants were randomly allocated to the intervention and comparison groups, the impact of the
intervention would be equally affected by regression to the mean [45].
One of the strengths of our study was that we managed to design and implement a field trial
within a primary healthcare system of a country in economic transition. Close to 50% of the people
with prediabetes at the beginning of the study had their glucose values normalized at the end of the
study. This shows that early lifestyle intervention programs may prevent or delay the development of
T2D and can be successfully integrated into the primary healthcare system. Lifestyle intervention trials
conducted in a controlled research setting have successfully shown that the incidence of T2D in high-risk
individuals with IGT can be approximately halved (DPS and DPP studies). Transversal implementations
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of the DPP within YMCA have shown similar results to ours, revealing an improvement especially in
the risk factors of T2D, such as overweight/obesity and levels of physical activity [11,12].
As a limitation, we were not able to assess changes in lifestyle or anthropometric measurements
in all of the study participants. In addition, the follow-up time of the participants ranged between 18
and 24 months only. Furthermore, the lack of generalizability to populations not included in the study,
such as persons from other provinces of Colombia, may limit external validity to the entire Colombian
population. Finally, as we lost close to 50% of the study participants during the follow-up, our study
may not have sufficient power to show a difference in reversion to normoglycemia or development
of T2D.
5. Conclusions
In conclusion, the DEMOJUAN project showed some benefits for glycaemia with significant 2hPG
fall, but failed to link it with the lifestyle interventions provided, compared with the control group.
Nevertheless, it has to be kept in mind that various factors affect the outcome of intervention programs
in a real population setting, as the conditions cannot be adequately controlled, such as in clinical
controlled trials. Therefore, this study adds an important piece of information to existing knowledge
resulting from lifestyle interventions of clinically controlled trials that can successfully be implemented
in real-life settings. Future studies should include an OGTT, combined with information on changes of
lifestyle and risk factors of T2D, of the study participants even when conducted within the primary
healthcare system.
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